PSMA-Positive Extracellular Vesicles Predict Disease Recurrence in Oligometastatic Castration-Sensitive Prostate Cancer Treated with Stereotactic Ablative Radiotherapy: Analysis of the ORIOLE trial.

E Horjeti, Y Kim, A Arafa,P Sutera,R Phillips,D Song,A P Kiess,P T Tran, S S Park, F Lucien-Matteoni

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览9

暂无评分

摘要

ProstEVs is the first blood biomarker of tumor burden that can prognosticate the risk of disease recurrence in omPC patients treated with SABR. While biomarker-guided trials are warranted, our validation study strengthens the clinical value of ProstEVs for personalized radiation therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要